高级检索
当前位置: 首页 > 详情页

Caveolin-1 regulates proliferation and metastasis of human breast cancer cells by activating Her-2

| 导出 |

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Dept Oncol, Shijiazhuang 050017, Peoples R China [2]Hebei Univ, Affiliated Hosp, Baoding 071000, Peoples R China [3]Hebei Med Univ, Dept Immunol, Key Lab Immune Mech & Intervent Serious Dis Hebei, Shijiazhuang 050017, Peoples R China [4]Bethune Int Peace Hosp, Dept Med Oncol, Shijiazhuang 050082, Peoples R China [5]BP Koirala Mem Canc Hosp, Dept Surg Oncol, Bharatpur, Nepal
出处:
ISSN:

关键词: Breast cancer Her-2 signal pathway caveolin-1 tumor suppressor

摘要:
Caveolin-1 is an important gene in breast cancer. Based on the analysis of cellular and molecular levels. Further discussions on the regulation of phosphorylation of Her-2 Caveolin-1 (Cav-1) and roles in the Akt/ERK pathway have been made. We selected 50 cases of invasive breast cancer tissues and used immunohistochemical techniques to assess cav-1, and to understand its relationship with EGFR, Her-2, Ki-67 expression as well as with other conventional clinico-pathological parameters. Ectopic expression of cav-1 in human breast cancer cell lines was performed to investigate changes in cellular proliferation, migration. The role of cav-1 in p-Her-2 expression and signaling was evaluated by Western blot. The expression of Cav-1 is associated with Cav-1 and Her-2/p-Her-2 and malignance in the breast tissue. The expression of Cav-1 is associated with lymph node metastasis and clinical stage. Cav-1 expression at higher levels of human breast cancer cell proliferation, migration and invasion ability has changed, with the increase of EGF stimulation. Cav-1 had no obvious effect on total expression of Her-2, but can regulate the phosphorylation level of Her-2, under the EGF stimulation; it can decline activation levels of Akt/ERK pathway. Cav-1 may promote the growth of breast cancer cells via enhancing EGF-induced Her-2 activation (phosphorylation) and downstream signal transduction.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验
JCR分区:
出版当年[2016]版:
Q4 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q4 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Dept Oncol, Shijiazhuang 050017, Peoples R China [2]Hebei Univ, Affiliated Hosp, Baoding 071000, Peoples R China
通讯作者:
通讯机构: [3]Hebei Med Univ, Dept Immunol, Key Lab Immune Mech & Intervent Serious Dis Hebei, Shijiazhuang 050017, Peoples R China [4]Bethune Int Peace Hosp, Dept Med Oncol, Shijiazhuang 050082, Peoples R China [*1]Department of Immunology, Key La-boratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Hebei Medical University, Shijiazhuang 050017, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:15100 今日访问量:0 总访问量:960 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持:重庆聚合科技有限公司 地址:保定市莲池区裕华东路212号